KalVista prices $160.1M public offering of common stock and pre-funded warrants

KalVista Pharmaceuticals, Inc.

Offering includes 7,016,312 shares at $15.25 and pre-funded warrants for 3,483,688 shares; gross proceeds $160.1M.
Net proceeds estimated at ~$150.1M to fund sebetralstat development and oral Factor XIIa program.
Cash, cash equivalents and marketable securities approximately $76M as of Jan 31, 2024 (preliminary).
Underwriters granted 30-day option to purchase up to 1,575,000 additional shares at same price.
Closing expected Feb 20, 2024; Jefferies, Leerink, Stifel, Cantor joint book-runners.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

KalVista Pharmaceuticals, Inc. entered into Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co. valued at approximately $150.1 million (effective 2024-02-14).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co.
Value: approximately $150.1 million
Effective: 2024-02-14

Exact text from the filing

On February 14, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co., as the representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell (i) an aggregate of 7,016,312 shares of its common stock (the “Shares”) and (ii) pre-funded warrants to purchase 3,483,688 shares of the Company’s common stock in lieu of its common stock (the “Pre-Funded Warrants”) to certain investors, to the Underwriters (the “Offering”).

View on SEC.gov

Browse all material agreements →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-038522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.